Using and interpreting cost-effectiveness acceptability curves: an example using data from a trial of management strategies for atrial fibrillation

BackgroundThe cost-effectiveness acceptability curve (CEAC) is a method for summarizing the uncertainty in estimates of cost-effectiveness. The CEAC, derived from the joint distribution of costs and effects, illustrates the (Bayesian) probability that the data are consistent with a true cost-effectiveness ratio falling below a specified ceiling ratio. The objective of the paper is to illustrate how to construct and interpret a CEAC.MethodsA retrospective cost-effectiveness analysis of the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) randomized controlled trial with 4060 patients followed for 3.5 years. The target population was patients with atrial fibrillation who were 65 years of age or had other risk factors for stroke or death similar to those enrolled in AFFIRM. The intervention involved the management of patients with atrial fibrillation with antiarrhythmic drugs (rhythm-control) compared with drugs that control heart rate (rate-control). Measurements of mean survival, mean costs and incremental cost-effectiveness were made. The uncertainty surrounding the estimates of cost-effectiveness was illustrated through a cost-effectiveness acceptability curve.ResultsThe base case point estimate for the difference in effects and costs between rate and rhythm-control is 0.08 years (95% CI: -0.1 years to 0.24 years) and -US$5,077 (95% CI: -$1,100 to -$11,006). The CEAC shows that the decision uncertainty surrounding the adoption of rate-control strategies is less than 1.7% regardless of the maximum acceptable ceiling ratio. Thus, there is very little uncertainty surrounding the decision to adopt rate-control compared to rhythm-control for patients with atrial fibrillation from a resource point of view.ConclusionThe CEAC is straightforward to calculate, construct and interpret. The CEAC is useful to a decision maker faced with the choice of whether or not to adopt a technology because it provides a measure of the decision uncertainty surrounding the choice.

[1]  A Briggs,et al.  Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane. , 1998, Health economics.

[2]  M Gent,et al.  Effect of Clinical Risk Stratification on Cost-Effectiveness of the Implantable Cardioverter-Defibrillator: The Canadian Implantable Defibrillator Study , 2001, Circulation.

[3]  P. Bower,et al.  Meta-analysis of data on costs from trials of counselling in primary care: using individual patient data to overcome sample size limitations in economic analyses , 2003, BMJ : British Medical Journal.

[4]  M. Sculpher,et al.  Representing uncertainty: the role of cost-effectiveness acceptability curves. , 2001, Health economics.

[5]  W C Black,et al.  The CE Plane , 1990, Medical decision making : an international journal of the Society for Medical Decision Making.

[6]  Andrew Briggs,et al.  Cost-effectiveness acceptability curves--facts, fallacies and frequently asked questions. , 2004, Health economics.

[7]  M J Al,et al.  Costs, effects and C/E-ratios alongside a clinical trial. , 1994, Health economics.

[8]  Anthony O'Hagan,et al.  Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Commentary: evaluating disease modifying treatments in multiple sclerosis. , 2003, BMJ : British Medical Journal.

[9]  A. Eden,et al.  Cost-Effectiveness of Lung-Volume-Reduction Surgery for Patients With Severe Emphysema , 2004 .

[10]  O C Ukoumunne,et al.  Cost-effectiveness of brief cognitive behaviour therapy versus treatment as usual in recurrent deliberate self-harm: a decision-making approach , 2003, Psychological Medicine.

[11]  A J Moskowitz,et al.  Problems with Interval Estimates of the Incremental Cost—Effectiveness Ratio , 1999, Medical decision making : an international journal of the Society for Medical Decision Making.

[12]  Cam Donaldson,et al.  An economic evaluation of activated protein C treatment for severe sepsis. , 2002, The New England journal of medicine.

[13]  B J O'Brien,et al.  Analysis of uncertainty in health care cost-effectiveness studies: an introduction to statistical issues and methods , 2002, Statistical methods in medical research.

[14]  N. Zethraeus,et al.  Definition, interpretation and calculation of cost-effectiveness acceptability curves. , 2000, Health economics.

[15]  A L Waldo,et al.  A comparison of rate control and rhythm control in patients with atrial fibrillation. , 2002, The New England journal of medicine.

[16]  B. Delaney,et al.  Cost effectiveness of initial endoscopy for dyspepsia in patients over age 50 years: a randomised controlled trial in primary care , 2000, The Lancet.

[17]  A R Willan,et al.  Confidence intervals for cost-effectiveness ratios: an application of Fieller's theorem. , 1996, Health economics.

[18]  B. O'brien,et al.  Cost-Effectiveness of Rhythm versus Rate Control in Atrial Fibrillation , 2004, Annals of Internal Medicine.

[19]  Philip D. Harvey,et al.  Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40 , 1998, BMJ.

[20]  A. Grant,et al.  To Be or Not To Be in Normal Sinus Rhythm: What Do We Really Know? , 2004, Annals of Internal Medicine.

[21]  M. Drummond,et al.  An economic evaluation of sequential i.v./po moxifloxacin therapy compared to i.v./po co-amoxiclav with or without clarithromycin in the treatment of community-acquired pneumonia. , 2003, Chest.

[22]  John Mullahy,et al.  Net Health Benefits: A New Framework for the Analysis of Uncertainty in Cost-Effectiveness Analysis , 1998 .

[23]  A H Briggs,et al.  Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. , 1997, Health economics.

[24]  Paul Fenn,et al.  Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41) , 2000, BMJ : British Medical Journal.

[25]  A H Briggs,et al.  Handling uncertainty when performing economic evaluation of healthcare interventions. , 1999, Health technology assessment.

[26]  A A Stinnett,et al.  Net Health Benefits , 1998, Medical decision making : an international journal of the Society for Medical Decision Making.